Semnur Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SMNR | NGEN | NMRA | SPRO | SION | MNOV | |
|---|---|---|---|---|---|---|
| Market cap | 98.99M | 145.16M | 106.35M | 62.31M | 168.41M | 71.37M |
| P/E (TTM) | — | — | — | 7.6 | — | — |
| Forward P/E | — | -4.0 | -0.9 | -1.0 | -1.7 | -2.8 |
| Price/book | -3.3 | 4.3 | 2.4 | 1.4 | 0.6 | 1.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −94.83% | −41.30% | −78.06% | −55.23% | −89.16% | +3.57% |
| Today | 0.00% | +2.27% | −0.86% | +2.88% | +2.19% | +2.11% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SMNR news ›Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination
Stock quotes, market indicators and the latest market news. Paul Hastings LLP is serving as legal counsel to Semnur and Winston & Strawn LLP is serving as legal counsel to the SPAC. For more information on Scilex Holding Company, refer to…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.